查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2138180

2026-2034年全球自體免疫疾病治療市場規模、佔有率、趨勢和成長分析報告

Global Autoimmune Disease Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 133 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球自體免疫疾病治療市場預計將從2025年的1,687.2億美元成長至2034年的2,311.5億美元，2026年至2034年的複合年成長率（CAGR）為3.56%。這個市場擴張的原因在於，人們日益認知到自體免疫疾病對醫療保健系統的負擔，並加大了對改善診斷和治療的投資。影響免疫系統的疾病盛行率不斷上升，推動了對標靶治療和先進療法的需求。製藥公司正在開發生物製藥、免疫調節劑、小分子藥物和其他精準療法。醫療保健支出的成長和獲得專科護理的機會增加也促進了治療方法的普及。病人和醫護人員對疾病認知的提高，有助於早期診斷和長期疾病管理。

藥物研發領域的技術進步為治療方案的開發創造了新的機會。研究人員日益關注與免疫功能障礙相關的生物路徑和分子標靶，從而實現更具針對性的治療策略。診斷檢測技術的進步有助於識別疾病特徵並指導治療方案的選擇。製藥公司也正在探索聯合治療和個人化治療策略，以應對個別患者的治療反應。擴大臨床研究並投資於新型治療平台有望增強自體免疫疾病治療的研發管線。

未來前景與持續創新、臨床成功、法規核准和患者可及性密切相關。標靶治療和個人化療法的進步有望改善複雜自體免疫疾病患者的治療選擇。隨著現有生物製藥面臨日益激烈的競爭，生物相似藥也可能影響治療可近性和醫療成本。預計各公司將投資於下一代免疫療法、生物標記和精準醫療方法。隨著研究不斷加深我們對自體免疫機制的理解，治療格局將更加多元化，並日益注重個人化疾病管理。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區特定分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球自體免疫疾病治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 系統
  • 管風琴

第5章 全球自體免疫疾病治療市場：依藥物類型分類

  • 市場分析、洞察與預測
  • 免疫抑制劑
  • 抗發炎藥
  • 皮質類固醇
  • 非類固醇類抗發炎藥
  • 其他

第6章 全球自體免疫疾病治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie Inc
    • Amgen Inc
    • Johnson & Johnson
    • Novartis AG
    • Roche Holding AG
    • Sanofi
    • Bristol Myers Squibb Company
    • Eli Lilly And Company
    • Pfizer Inc
    • AstraZeneca PLC
    • Merck & Co.Inc
    • UCB SA
    • Biogen Inc
    • Boehringer Ingelheim
    • Takeda Pharmaceutical Company Limited
    • Janssen Pharmaceuticals
    • Gilead SciencesInc
    • Teva Pharmaceutical Industries Ltd
    • Viatris Inc
    • Galapagos NV
簡介目錄
Product Code: VMR112115091

The global autoimmune disease therapeutics market size is expected to reach USD 231.15 Billion in 2034 from USD 168.72 Billion in 2025, growing at a CAGR of 3.56% during 2026-2034.This market is expanding as healthcare systems increasingly recognize the burden of autoimmune disorders and invest in improved diagnosis and treatment options. Growing prevalence of conditions affecting the immune system is supporting demand for targeted therapies and advanced treatment approaches. Pharmaceutical companies are developing biologics, immunomodulators, small-molecule therapies, and other precision treatment options. Increasing healthcare expenditure and improved access to specialist care are also supporting treatment adoption. Greater disease awareness among patients and healthcare professionals is encouraging earlier diagnosis and longer-term disease management.

Technological advances in drug discovery are creating new opportunities for therapeutic development. Researchers are increasingly focusing on biological pathways and molecular targets associated with immune dysfunction, enabling more targeted approaches. Improvements in diagnostic testing can help identify disease characteristics and support treatment selection. Pharmaceutical companies are also exploring combination therapies and personalized treatment strategies to address differences in patient response. Expanding clinical research and investment in novel therapeutic platforms are expected to strengthen the pipeline for autoimmune disease treatments.

Future prospects are closely linked to continued innovation, clinical success, regulatory approvals, and patient access. Increasing development of targeted and personalized therapies could improve treatment options for patients with complex autoimmune conditions. Biosimilars may also influence treatment accessibility and healthcare costs as established biologic therapies face greater competition. Companies are expected to invest in next-generation immunotherapies, biomarkers, and precision medicine approaches. As research improves understanding of autoimmune mechanisms, the therapeutic landscape is likely to become more diversified and increasingly focused on individualized disease management.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

  • Systemic
  • Organ-specific

By Drug Type

  • Immunosuppressants
  • Anti-Inflammatory Drugs
  • Corticosteroids
  • Nonsteroidal anti-inflammatory drugs
  • Others

COMPANIES PROFILED

  • AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Roche Holding AG, Sanofi, Bristol Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., UCB S.A., Biogen Inc., Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Galapagos NV

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Disease Type
  • 4.2. Systemic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Organ-specific Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Type
  • 5.2. Immunosuppressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Anti-Inflammatory Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Nonsteroidal anti-inflammatory drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Disease Type
    • 6.2.2 By Drug Type
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Disease Type
    • 6.3.2 By Drug Type
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Spain
    • 6.3.8 Russia
    • 6.3.9 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Disease Type
    • 6.4.2 By Drug Type
    • 6.4.3 China
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 India
    • 6.4.7 Australia
    • 6.4.8 South East Asia
    • 6.4.9 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Disease Type
    • 6.5.2 By Drug Type
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Disease Type
    • 6.6.2 By Drug Type
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 AbbVie Inc
    • 8.2.2 Amgen Inc
    • 8.2.3 Johnson & Johnson
    • 8.2.4 Novartis AG
    • 8.2.5 Roche Holding AG
    • 8.2.6 Sanofi
    • 8.2.7 Bristol Myers Squibb Company
    • 8.2.8 Eli Lilly And Company
    • 8.2.9 Pfizer Inc
    • 8.2.10 AstraZeneca PLC
    • 8.2.11 Merck & Co.Inc
    • 8.2.12 UCB S.A
    • 8.2.13 Biogen Inc
    • 8.2.14 Boehringer Ingelheim
    • 8.2.15 Takeda Pharmaceutical Company Limited
    • 8.2.16 Janssen Pharmaceuticals
    • 8.2.17 Gilead SciencesInc
    • 8.2.18 Teva Pharmaceutical Industries Ltd
    • 8.2.19 Viatris Inc
    • 8.2.20 Galapagos NV